Noxopharm is an Australian-based drug development company with offices in Melbourne and Sydney. It intends to focus on two areas of drug technology. The first is the potential benefit to cancer patients in being able to overturn resistance to standard of care chemotherapies and radiotherapies. NOX66 is the first pipeline drug candidate, with later generation drug candidates under investigation in an R&D program.

The second area relates to drug-delivery technology behind NOX66 and the opportunity it offers to exploit the broader therapeutic opportunities of isoflavonoid compounds.

Latest Media Releases

Noxopharm, 2018 Annual Report

27/09/2018 09:32:00

CHAIRMAN'S LETTER Dear Shareholder, This financial year has been one of increasing momentum for Noxopharm with three clinical studies underway, important additional programs being planned, a…

Latest News